TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04687566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will take the placebo pills, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
Study: NCT03647072
Drug: CHOP Plus Lanzoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP plus Lanzoprazole 60 mg
Study: NCT00004901
Drug: ethynyluracil
Normalized name: 5-Ethynyluracil
DrugBank: Eniluracil (DB03516)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004901
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01638403
Drug: BF2.649
Approvals — FDA: no, EMA: no, PMDA: no
Description: BF2.649 is provided in capsules. One-quarter or one-half of BF2.649 tablet at 20 mg (corresponding to 5-, and 10 mg, respectively).~Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.
Study: NCT01638403
Drug: palcebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~placebo consist of identical capsules containing lactose only. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.
Study: NCT03604575
Drug: Humalog®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02451982
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2 IV
Study: NCT00033306
Drug: Fluoropyrimidine
Normalized name: Fluoropyrimidine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01281956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00359177
Drug: GW679769
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW679769 will be available in dose strength of 50 mg tablets. Subjects will receive two tablets of 50 mg orally once daily in the morning
Study: NCT00939237
Drug: Ateronon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
Study: NCT00939237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00999700
Drug: docetaxel - cisplatin - 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21
Study: NCT02488967
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02488967
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01538394
Drug: Placebo (nicotine patches)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01216904
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo patch to be worn 16 hours per day
Study: NCT02112799
Drug: NVR 3-778
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02112799
Drug: Placebo for NVR 3-778
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic the NVR 3-778 capsule
Study: NCT01257386
Drug: Asacol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg tablets
Study: NCT02456961
Drug: Dextralink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin 0,1% + Dextran T-500
Study: NCT00984334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03373318
Drug: Plasmalyte
Normalized name: PLASMALYTE A
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose and the speed of administration depend on the age, weight, clinical and biological status of the patient and the concomitant treatment. The recommended dose for adults, the elderly and adolescents: from 500 ml to 3 liters / 24 hours.
Study: NCT02889809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.
Study: NCT02889809
Drug: Short Acting Beta 2 Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.
Study: NCT02581826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No column specified.
Study: NCT00003116
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide IV twice a day on days -4 and -3
Study: NCT01975259
Drug: Oral Glucose Tolerance test (75g 2-hour)
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standard 2-hour oral glucose tolerance test where fasted patients (10hours overnight) consume a 75g glucose solution \& have glucose levels recorded up to every 30 mins for 2hours
Study: NCT01975259
Drug: Modified Oral Glucose Tolerance Test (50g 4-hours)
Normalized name: glucose 0.4 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 4-hour version of the oral glucose tolerance test where fasted patients (10hours overnight) consume a 50g of glucose solution \& have glucose levels recorded up to every 5mins as well pancreatic and incretin responses at 10 fixed time points.
Study: NCT01975259
Drug: Hyperglycemic clamp with placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).~After 60mins an infusion of normal saline will be commenced as a placebo infusion. It will be infused at a rate so that the total volume of fluid is similar to that infused during the other two hyperglycemic clamp interventions. Subjects will be blinded to what infusion they are receiving.
Study: NCT03162094
Drug: Placebo (vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular topical administration of placebo (vehicle Ophthalmic Solution)
Study: NCT01132222
Drug: Ibuprofen + Pseudoephedrine Hydrochloride
Normalized name: ibuprofen / pseudoephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
Study: NCT01746199
Drug: cotrimoxazole daily prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01041677
Drug: R256918
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg capsule twice daily
Study: NCT01041677
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule twice daily
Study: NCT01041677
Drug: R256918
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg capsule twice daily
Study: NCT00464295
Drug: Capecitabine in HCC
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00307671
Drug: prednisone, methylprednisolone,cyclophosphamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment conventional
Study: NCT00307671
Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: reduction dose
Study: NCT00307671
Drug: Mycophenolate mofetil,methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: in the treatment conventional and in the reduction dose
Study: NCT02035488
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin dry powder 30 mg inhalation per dose; Dose escalation: 30-60-120 and 240 mg, each one time. One dose per week.
Study: NCT03320941
Drug: LIK066
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIK066 will be supplied in different doses as tablets to be taken orally daily.
Study: NCT03320941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as tablets to be taken daily orally.
Study: NCT01753323
Drug: KAF156
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAF156 was supplied as tablets for oral use.
Study: NCT00774306
Drug: phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin is a anti-seizure medication. Participants will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
Study: NCT00927537
Drug: Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide
Normalized name: hydrochlorothiazide / telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients under daily life treatment receiving Kinzalplus according to local drug information.
Study: NCT03362684
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-4 every 2 weeks
Study: NCT00964015
Drug: 0.9% Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03745651
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib matching vehicle cream.
Study: NCT02884921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03360071
Drug: Allergen Immunotherapy Extract
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen Immunotherapy treatment mixture to be delivered subcutaneously
Study: NCT01443546
Drug: Lupron Trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: leuprolide acetate 2 mg SQ
Study: NCT03490942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo solution is a non-active formulation containing excipients only.
Study: NCT02503839
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclooxygenase-2 inhibitor. Anti-inflammatory
Study: NCT00952016
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: study subjects will receive methotrexate intravenously on day 1 and day 8 of a 3 weekly cycle.
Study: NCT00201214
Drug: Citrulline
Normalized name: Citrulline
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with dosage escalation study 50mg/kg, 100mg/kg, 150mg/kg IV at 6, 12, 24, 48 hours post operative. Phase II - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with 9mg/kg/hr continuous IV starting 4 hours post bolus and infusing for 48 hours or discharge from PCCU.
Study: NCT04047849
Drug: Antibiotics, oral Azithromycin and oral Amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500mg day one followed by 250mg per day for 4 more days) and amoxicillin (500mg orally three times daily for 7 days) for a total course of seven days of antibiotic therapy
Study: NCT01272375
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04764793 250/50 using inhaler A
Study: NCT01272375
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04764793 250/50 using inhaler A
Study: NCT01272375
Drug: Treatment G
Normalized name: VanaLice Lice Killing Treatment Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04764793 250/50 using inhaler B
Study: NCT02295293
Drug: Rhus Coriaria L. (Rhus)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
Study: NCT04362111
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive normal saline placebo subcutaneously every 6-12 hours for period of 10 days
Study: NCT00482417
Drug: MK0359
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02522299
Drug: GSK2269557
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2269557 500 mcg blended with lactose per blister and will be administered using a DISKUS dry powder inhaler device. Since GSK2269557 will no longer be manufactured for use with the DISKUS device, it will be replaced with ELLIPTA Device. Subjects will receive GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
Study: NCT02522299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose will be administered using a DISKUS and ELLIPTA dry powder inhaler device
Study: NCT04161872
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01607294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Daily for 4 weeks
Study: NCT01485302
Drug: SAR228810
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study: NCT01485302
Drug: SAR228810
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Study: NCT02704559
Drug: DWC20155
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03518034
Drug: AndroGel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: testosterone administered topically
Study: NCT02625922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo i.v infusion
Study: NCT01527500
Drug: LFG316
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFG316 5 mg/50 μL solution for IVT injection,
Study: NCT01527500
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)
Study: NCT01110551
Drug: Placebo (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline administered subcutaneously.
Study: NCT01110551
Drug: Placebo (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline administered intradermally.
Study: NCT00187122
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See Detailed Description section for description of treatment plan.
Study: NCT00187122
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Detailed Description section for description of treatment plan.
Study: NCT00187122
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See Detailed Description section for description of treatment plan.
Study: NCT01463397
Drug: SAR292833
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT02843698
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT01110785
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01642771
Drug: Docetaxel/capecitabine followed by XEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle 1-3: Docetaxel i.v. 75 mg/m2, Capecitabine, p.o., 1000 mg/m2，b.i.d (take Capecitabine for 2 weeks and withdraw for 1 week) (One cycle = 21 days); Cycle 4-6: Capecitabine, i.v. 1000 mg/m2, b.i.d (take for 2 weeks and withdraw for 1 week),Epirubicin, i.v. 75 mg/m2, Cyclophosphamide, i.v. 500 mg/m2 (One cycle = 21 days)
Study: NCT03023878
Drug: Investigator's Choice Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the run-in period participants received 6 cycles of standard of care rituximab-chemotherapy dosed per investigator's institution standard as follows:~* R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,prednisone)~* R-DA-EPOCH (rituximab and dose adjusted-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) or~* R-CHOEP (rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide).
Study: NCT00656578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, solution
Study: NCT03385369
Drug: MEDI0382
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of MEDI0382
Study: NCT03385369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo
Study: NCT01812837
Drug: Aminolevulinic Acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
Study: NCT03029689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets of placebo) once daily plus current ART during 48 weeks from randomization.
Study: NCT03029689
Drug: Current ART
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-drug antiretroviral treatment including PI/r/c or NNRTI
Study: NCT02749799
Drug: DFD-01 (betamethasone dipropionate) Spray, 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
Study: NCT00524693
Drug: Placebo granules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03111615
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase Inhibitor to start immediately after diagnosis of a Luminal Invasive Breast Carcinoma Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.~Venlafaxin 75 mg is to be administrated cases indicated
Study: NCT02634983
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.
Study: NCT02634983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT03705845
Drug: placebo softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each placebo softgel of 430 mg olive oil will contain no TT or tocopherols at detectable levels.
Study: NCT00010803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill twice daily
Study: NCT00044525
Drug: BAY59-8862 (Cytotoxic Taxane)
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 h intravenous infusion every 3 weeks
Study: NCT02684942
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
Study: NCT00523926
Drug: TMC207
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01487239
Drug: [14C]-GDC-0980
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 uCi of \[14C\]-GDC-0980 in total dose of 10 mg GDC-0980
Study: NCT03001466
Drug: urea-loaded nanoparticles eye drops
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop five times a day for 8 weeks
Study: NCT03129295
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet four times a day for 3 days
Study: NCT03152474
Drug: Solumedrol 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed Intravenous every 8 hrs.
Study: NCT00002525
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perioperative 5-FU: 600 mg/m\^2/d x 7 days continuous IV, beginning within 24 hours of surgery~After surgery, 5-FU was given 425 mg/m\^2 IV push on days 1-5
Study: NCT00002525
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given after surgery at dose of 20mg/m\^2 IV push on days 1-5
Study: NCT05047484
Drug: ALXN2050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder-in-capsule (PIC).
Study: NCT05047484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIC.
Study: NCT01505179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
Study: NCT00350779
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to sitagliptin 100mg tablet each day for 54 weeks.
Study: NCT00543634
Drug: Premarin/MPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/2.5 mg X4
Study: NCT00543634
Drug: Premarin/MPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/5 mg X 2
Study: NCT02326740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02431832
Drug: Augmentin tab
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01369147
Drug: Parenteral Nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PN dose will be written for each 24-hr period taking into account any kilocalories (kcal) provided as part of standard of care from propofol, clevidipine, dextrose-containing IV fluid exceeding 500 mL/day, and enteral feedings.
Study: NCT01369147
Drug: Enteral feeding
Normalized name: enteral feeding dispenser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition is caloric intake through the gastrointestinal (GI) tract via food consumed through the mouth or a feeding tube delivering nutrition directly to the stomach or small intestines. The PN dose will be written for each 24-hr period taking into account calories provided from any enteral feedings.
Study: NCT01897792
Drug: Placebo (for Vitamin E)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill administered to mimic Vitamin E
Study: NCT00911183
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00911183
Drug: liposome-encapsulated doxorubicin citrate
Normalized name: liposomal encapsulated paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01096680
Drug: SPD489 70 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 70 mg
Study: NCT00203502
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg per meter squared, IV every 21 days
Study: NCT02450279
Drug: technetium-99m - Diethylenetriaminepentaacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005908
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m\^2 will be diluted in 100 mL 0.9% normal saline (NS) and administered intravenously over 30 minutes on day 1